Search the Newsreel

Take-Two Interactive Software, Inc. reports results for the quarter ended June 30 - Earnings Summary

Take-Two Interactive Software, Inc. has released its earnings summary for the quarter that concluded on June 30. The full article detailing these results is available on TradingView, sourced from Reuters and Refinitiv.

Why Take-Two Is Keeping Bookings Guidance Steady Even as ‘GTA VI’ Preorders Are ‘Unprecedented’

Take-Two reiterates fiscal 2027 guidance for net bookings even as ‘Grand Theft Auto VI’ preorders began June 25. Continue Reading

Take-Two (TTWO) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, Take-Two Interactive (TTWO) reported revenue of $1.39 billion, down 2.6% over the same period last year. EPS came in at $0.36, compared to $0.61 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …

Take-Two’s (NASDAQ:TTWO) Q2 CY2026 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations Significantly

Take-Two's (NASDAQ:TTWO) Q2 CY2026 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations Significantly Video game publisher Take Two (NASDAQ:TTWO) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 7.8% year on year to $1.53 billion. On the other hand, …

Update: Take-Two Interactive Software Fiscal Q1 Loss Widens, Revenue Increases; Fiscal 2027 Guidance Reiterated

(Updates with Grand Theft Auto release date in seventh paragraph.) Take-Two Interactive Software PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? …

Take-Two shares dip as soft guidance overshadows Q1 beat ahead of GTA VI

Investing.com -- Take-Two Interactive Software (NASDAQ: TTWO) delivered a solid start to its fiscal year, but a cautious outlook for upcoming quarters caused investors to pump the brakes. The video game giant posted first-quarter net bookings of $1.39 billion—down 3% year-over-year, but beating its …

Press Release: Take-Two Interactive Software, Inc. Reports Results for Fiscal First Quarter 2027

This press release details Take-Two Interactive Software, Inc.'s financial results for its fiscal first quarter of 2027. It will likely include key financial metrics, performance highlights, and possibly future outlook or guidance from the company.

Form 8K Take-Two Interactive Software Inc For: 7 August By Investing.com

Investing.com reports on a Form 8K filing by Take-Two Interactive Software Inc. for August 7. The brief article, published on August 7, 2026, includes market data for various indices, commodities, and stocks.

Take-Two sticks to annual bookings outlook, says on track for 'GTA VI' November launch

Take-Two Interactive maintained its annual bookings forecast and reiterated the November 19 launch date for "Grand Theft Auto VI." Despite projecting current-quarter bookings below Wall Street estimates due to a lack of new titles, the company expects "GTA VI" to be a major revenue …

Take-Two touts 'unprecedented GTA VI pre-orders', but maintains bookings target

By Deborah Mary Sophia Aug 7 (Reuters) - Take-Two Interactive said on Friday it is seeing "unprecedented" demand for "Grand Theft Auto VI", reinforcing investor expectations of a major boost to the company ‌from the blockbuster title's planned release in November. Shares of Take-Two …

(TTWO) Take-Two Interactive Software, Inc. Expects Q2 Revenue Range $1.42B - $1.47B

Take-Two Interactive Software, Inc. (TTWO) anticipates its Q2 revenue to fall within the range of $1.42 billion to $1.47 billion. This announcement follows their fiscal Q1 results where the loss widened but revenue increased. The company has also reiterated its fiscal 2027 guidance, with …

Grand Theft Auto VI set for Nov. 19 as Take-Two repeats $8.0B-$8.2B outlook

Take-Two Interactive Software, Inc. reported its first-quarter fiscal year 2027 results, with net bookings slightly above guidance at $1.39 billion. The company reiterated its fiscal year 2027 net bookings outlook of $8.0 billion to $8.2 billion, driven by strong performance and the anticipated launch …

Take-Two Interactive Software, Inc. Reports Results for Fiscal First Quarter 2027

Fiscal first quarter Net Bookings were $1.39 billion, slightly above Company's guidance range Company updates fiscal year 2027 outlook and reiterates expectation for Net Bookings of $8.0 to $8.2 billion NEW YORK, August 07, 2026--(BUSINESS WIRE)--Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today reported results for …

Earnings Flash (TTWO) Take-Two Interactive Software, Inc. Reports Q1 Revenue $1.53B

Take-Two Interactive Software, Inc. (TTWO) announced its first-quarter revenue of $1.53 billion. This earnings flash provides a quick overview of the company's financial performance for the quarter.

Pacer Advisors Inc. Reduces Stake in Take-Two Interactive Software, Inc. $TTWO

Pacer Advisors Inc. significantly reduced its stake in Take-Two Interactive Software by 44.0% in the first quarter, selling 12,147 shares and retaining 15,451 shares valued at $3.05 million. Despite this institutional selling and additional insider sales totaling $128.4 million, analyst sentiment remains largely positive …

EURO MENKUL KIYMET YATIRIM ORTAKLIĞI A.Ş.(EUYO) Sorumluluk Beyanı (Konsolide Olmayan) 6 Ağustos 2026

Take-Two Interactive Software (NASDAQ:TTWO) Updates Q2 2027 Earnings Guidance

Take-Two Interactive (TTWO) Q1 Earnings and Revenues Top Estimates

TAK|Takeda Pharmaceutical Co Ltd|Price:17.450|Chg%:+0.430

Here’s How Much You Would Have Made Owning Take-Two Interactive Stock In The Last 15 Years

Take-Two Interactive (NASDAQ: TTWO) has shown significant market outperformance over the last 15 years, with an average annual return of 22.21%. An initial investment of $100 in TTWO stock 15 years ago would now be worth $2,068.24, highlighting the power of compounded returns. The …

DENIZ YATIRIM - KAP Haberleri - 2026-08-06 tarihli

Take-Two Interactive Software, Inc. (TTWO) stock price, news, quote and history

This page provides a comprehensive overview of Take-Two Interactive Software, Inc. (TTWO), including its current stock price, financial performance, company profile, and recent news. The company develops and publishes a wide range of interactive entertainment solutions, including popular franchises like Grand Theft Auto and …

Take-Two Interactive Software Inc. stock underperforms Thursday when compared to competitors

Take-Two Interactive Software Inc. (TTWO) shares fell by 1.04% on Thursday, closing at $232.47, underperforming a generally down day for the stock market. This marks the third consecutive day of losses for the company's stock, as the S&P 500 Index and Dow Jones Industrial …

Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead

Takeda's oral orexin receptor agonist, oveporexton (marketed as Orzeyful), has received FDA approval for narcolepsy type 1, making it the first disease-modifying therapy for the condition. The drug targets the root cause of narcolepsy by binding to the orexin receptor 2, improving wakefulness and …

Takeda approval ushers in new wave of sleep drugs

The FDA has approved Takeda's Orzeyful, a drug for Type 1 narcolepsy that targets orexin-2 protein. This approval marks the entry of a potentially multibillion-dollar class of sleep medicines. Orzeyful's launch is pending DEA scheduling, while other companies like Alkermes and Eli Lilly are …

Takeda wins U.S. FDA approval for narcolepsy drug ORZEYFUL

Takeda Pharmaceutical has received U.S. FDA approval for ORZEYFUL (oveporexton) to treat adults with narcolepsy type 1, making it the first approved orexin agonist for the disorder. The approval, granted on August 5, 2026, is based on positive Phase 3 trial results showing significant …

Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful

Takeda has received FDA approval for Orzeyful (oveporexton), a first-in-class, twice-daily tablet for adults with narcolepsy type 1 (NT1). This treatment addresses the root cause of the condition by mimicking the body's orexin cycle. Takeda anticipates peak sales for Orzeyful to be between $2 …

Take-Two Interactive Software Target of Unusually Large Options Trading (NASDAQ:TTWO)

Take-Two Interactive Software (NASDAQ:TTWO) experienced an unusually large surge in options trading, with call option activity increasing by 413% compared to its average volume. Despite a slight dip in stock price, analysts maintain a "Buy" rating with an average price target of $294.44, though …

Takachiho KohekiLtd (TSE:2676) Stock Rerates As Profit Margin Improves

Takeda’s Orzeyful approved in US as first-in-class orexin treatment for narcolepsy Type 1

The FDA has approved Takeda's Orzeyful (oveporexton) as the first medication to directly address the loss of orexin signaling in Narcolepsy Type 1. Unlike previous treatments that only offered symptomatic relief, Orzeyful targets the underlying cause by activating the brain's orexin receptor 2 (OX2R). …

Takeda Wins FDA Nod For ORZEYFUL, First Orexin Therapy For Narcolepsy Type 1

(RTTNews) - Takeda (TAK) announced that the U.S. FDA has approved ORZEYFUL, an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1) in adults. Narcolepsy type 1 is a rare, chronic neurological disorder caused by orexin deficiency, affecting an …

Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict

Takeda Pharmaceuticals is arguing that an $885 million antitrust verdict against it, related to delaying generic competition for its IBS drug Amitiza, should be reduced. The drugmaker contends that rebates it paid and Medicare subsidies received by health plans should be factored into the …

US FDA approves Takeda's sleep disorder pill

The U.S. Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals' oral drug, Orzeyful, for narcolepsy, making it the first treatment to target all symptoms of the rare sleep disorder. Orzeyful works by directly addressing the loss of orexin signaling, which is the cause …

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda announced that the U.S. FDA has approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for treating narcolepsy type 1 (NT1) in adults. This first-in-class medicine targets the underlying orexin deficiency, offering holistic treatment beyond symptom relief. The availability of ORZEYFUL is …

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

The FDA has approved Takeda's narcolepsy drug, Orzeyful, a twice-daily pill that is an orexin receptor agonist. This approval is significant as it marks a new class of treatment for narcolepsy type 1, offering an alternative to existing therapies which have risks of misuse …

Take-Two Set to Report Q1 Earnings: What's in the Cards for the Stock?

Take-Two Interactive Software TTWO is scheduled to report its first-quarter fiscal 2027 results on Aug. 7, 2026. For the first quarter of fiscal 2027, Take-Two expects GAAP net revenues between $1.45 billion and $1.50 billion. The company projects a loss per share of 23 …